130 results about "Pramipexole" patented technology

A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm−2 at a solid fraction representative of the tablet.

Pharmaceutical compositions of (R)-pramipexole and methods and kits of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.

Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and / or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg / kg / daily, preferably 0.5-50 mg / kg / daily, and most preferably 1-10 mg / kg / daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg and / or by continuous intravenous infusions between 10 mg / day and 500 mg / day.

The process for the preparation of pramipexole base and / or its pharmaceutically acceptable salts, especially the hydrochloride salt, in the alkylation reaction of (S)-(−)2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with an alkylating agent, wherein the reaction is carried out in the absence of a base, and in a solvent from which the resulting N-monoalkylated product selectively precipitates out as a salt. After isolation from the reaction mixture, the N-monoalkylated product is converted a) into the free pramipexole base upon treatment with an inorganic base and is then converted into another pharmaceutically acceptable pramipexole salt; or b) directly into another pharmaceutically acceptable pramipexole salt or the hydrate thereof.

A novel process for the preparation of S(−)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexole).

An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and / or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.

Formulations and methods of use thereof for restoring neuronal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg / kg / daily, preferably 0.5-50 mg / kg / daily, and most preferably 1-10 mg / kg / daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg, and / or by continuous intravenous infusions between 10 mg / day and 500 mg / day.

An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water swelling polymers, wherein one of the polymers is pregelatinized starch, and wherein another one of the polymers is an anionic polymer.

The invention relates to the use of pramipexole and the pharmacologically acceptable acid addition salts thereof as well as hydrates and solvates thereof, for preparing a pharmaceutical composition for the prevention and / or treatment of HIV encephalopathy.

Compositions of predetermined amounts of R(+) pramipexole and S(-) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.

The invention is directed to the use of an extended release tablet formulation for pramipexole.

The invention discloses a preparation process of pramipexole, namely enantiomers or racemates of 2-amino-6-acrylamido-4,5,6,7-tetrahydrobenzothiazole. The pramipexole is prepared from 2-amino-6-propionylamino-4,5,6,7-tetrahydrobenzothiazole as the raw material by the reduction reaction with a reducing agent. The process has easy operation, and mild reaction condition, is easy to control, and greatly improve the safety of production.

Pharmaceutical compositions of (R)-pramipexole and methods and kits of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.

The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof.

An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.

The invention relates to a method for preparing 4- substituted acylamino cyclohexanone through oxidizeing 4- substituted acylamino cyclohexanol. The 4- substituted acylamino cyclohexanone prepared by the method can be used for preparing Pramipexole. The method comprises the following steps: adding 4- substituted acylamino cyclohexanol as is shown in formula I, catalyst 2, 2, 6, 6- tetramethyl piperidine - nitrogen - oxide, NaBr, into organic solvent, then dropwise adding sodium hypochlorite water solution for reaction until oxidation reaction is complete, and obtaining the 4- substituted acylamino cyclohexanone shown in formula II after separation and purification to reaction solution; and the method provided by the invention mainly has the following benefits: a novel chemical synthesis method for producing key intermediate of medicine Pramipexole is found, the route is enabled to be more reasonable, the reaction conditions are milder, the yield is higher, and the method is environment-friendly and suitable for large scale industrial production.

A pharmaceutical composition for transdermal or transmucosal delivery of an active agent to treat a movement disorder such as Parkinson's disease. The composition provides enhanced transdermal or transmucosal delivery of the active agent by including an alkanolamine as a permeation enhancer with a carrier of water and at least one short-chain alcohol and with the composition having a neutral pH. The composition provides controlled and sustained release of the active agent suitable for daily administration.

The invention relates to a pramipexole preparation which comprises pramipexole or a medicinal salt thereof which accounts for 0.05 to 1.5% of the total weight of the preparation and is used as an active component, microcrystalline cellulose and pregelatinized starch, wherein a weight ratio of microcrystalline cellulose and pregelatinized starch is 1:1 to 1: 5. The invention also relates to a preparation method for the pramipexole preparation. The preparation prepared by using the preparation method has low hygroscopicity and is beneficial for storage; and the preparation method has good production feasibility and is suitable for commercial production.

The invention relates to an active substance combination consisting of clonidine and pramipexole for treating Restless Leg Syndrome.

The invention relates to a pramipexole sustained-release preparation for injection and a preparation method thereof, belonging to the technical field of medicines. The preparation method comprises thefollowing steps: dissolving a main drug and an internal water phase additive into water for injection so as to form a main drug-containing internal water phase solution; dissolving PLGA and an organic phase additive into an organic solvent so as to form an organic phase solution; mixing the main drug-containing internal water phase solution with the organic phase solution and carrying out ultrasonic treatment so as to form a primary water-in-oil emulsion; adding the primary water-in-oil emulsion into an external water phase solution, and carrying out stirring so as to form a water-in-oil-in-water multiple emulsion; solidifying the water-in-oil-in-water multiple emulsion so as to form microspheres, carrying out centrifugal washing, and collecting the microspheres so as to obtain wet microspheres; adding a gel solution and a freeze-drying protective agent into the wet microspheres so as to obtain a microsphere gel solution; and subjecting the microsphere gel solution to freeze-drying. The pramipexole sustained-release preparation for injection provided by the invention has high drug loading capacity and good temperature sensitivity and biological compatibility, sustainably and stably releases drugs, can effectively reduce the occurrence of motor complications, and improves the compliance of a patient.

The invention discloses a transdermal patch containing pramipexole. The transdermal patch comprises a medicine carrying pressure-sensitive adhesive layer, the pramipexole, solvent and penetration enhancer, wherein the medicine carrying pressure-sensitive adhesive layer comprises acrylate pressure-sensitive adhesive containing carboxyl base groups and acrylate pressure-sensitive adhesive containing hydroxyl base groups, which form mixed pressure-sensitive adhesive; the pramipexole is dissolved in the acrylate mixed pressure-sensitive adhesive, with the content being 10 to 30 weight percent; the content of the mixed pressure-sensitive adhesive is 50 to 80 weight percent; the content of the solvent is 5 to 20 weight percent; the content of the penetration enhancer is 2 to 15 weight percent. The pramipexole can be dissolved in a mixed pressure-sensitive adhesive patch in a high concentration way and is not crystallized, the medicine availability is high, the pramipexole has good stability in pressure-sensitive adhesive matrix, and can be continuously administrated for 5 to 7 days in a transdermal way at a relatively stable permeation rate of being larger than 5.0 micrograms / cm2 / h, and the application area of a pramipexole patch is smaller than 40cm2.

The present invention belongs to the technical field of medicine, and provides a pramipexole oral liquid and a preparation method thereof. Pramipexole is a dopamine D2 receptor agonist for treatment of Parkinson's disease; early symptoms of the Parkinson's disease comprise static tremor, myotonia, bradykinesia, and abnormal posture and gait; and moderate and advanced symptoms of the Parkinson's disease patients often comprise difficult chewing and swallowing. With the pramipexole oral liquid of the present invention, medication compliance of patients is easily improved, and a therapeutic effect is improved.

The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for reducing excessive food intake.